Compare STRA & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | LBRX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 1996 | 2025 |
| Metric | STRA | LBRX |
|---|---|---|
| Price | $82.39 | $34.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $96.67 | $57.30 |
| AVG Volume (30 Days) | 208.0K | ★ 322.1K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | 15.85 | ★ 98.22 |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $997,137,000.00 | N/A |
| Revenue This Year | $2.51 | N/A |
| Revenue Next Year | $2.96 | N/A |
| P/E Ratio | $25.22 | ★ N/A |
| Revenue Growth | ★ 57.23 | N/A |
| 52 Week Low | $69.70 | $14.32 |
| 52 Week High | $89.73 | $50.16 |
| Indicator | STRA | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 34.13 |
| Support Level | $77.55 | $26.75 |
| Resistance Level | $85.36 | $49.74 |
| Average True Range (ATR) | 2.20 | 1.99 |
| MACD | 0.46 | -0.56 |
| Stochastic Oscillator | 94.72 | 24.73 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.